RB1 and breast cancer: In the same direction, a study conducted on triple negative BC cell lines, showed that administration of Palbociclib together with the genotoxic agent doxorubicin (anthracycline) mitigated the efficacy of the chemotherapy, protecting Rb-proficient cells from the cytotoxic effects of doxorubicin (83).